



Invited Faculty

A. Grossman (London, GB)
C. Toumpanakis (London, GB)
M. Serke (Marburg, GER)
B. Wiedenmann (Berlin, GER)
Weber M (Mainz, GER)
E. Baudin (Paris, FR)
F. Barlesi (FR)
G. Juste (Valladolid, ES)
W. W. De Herder (Rotterdam, NL)
DJ Kwekkeboom (Rotterdam, NL)
L. Hofland (Rotterdam, NL)
K. Oberg (Uppsala, SWE)
B. Eriksson (Uppsala, SWE)
D. Granberg (Uppsala, SWE)
P. Ferolla (Perugia, IT)
L. Bodei (Milan, IT)
N. Fazio (Milan, IT)
F. Rea (Padova, IT)
M. Lucchi (Pisa, IT)
D. Ferone (Genova, IT)
D. Giuffrida (Catania, IT)
A. Faggiano (Naples, IT)
P. Filosso (Turin, IT)
A. Colao (Naples, IT)
K. Syrigos (Athens, GRE)

Centers participant to the survey:

St Bartholomew's Hospital London, GB;
Royal Brompton Hospital, London, GB;
Royal Infirmary Hospital, London, GB;
Institute Gustave Roussy, Paris, FR;
Université Méditerranée Marseille, FR;
Charité-Universitätsmedizin Berlin, GER;
Pneumologie Thorakale Onkologie,
Marburg, GER;
Mainz Universität, GER;
Università di Torino, IT;
Gruppo Multidisciplinare per la Diagnosi
e terapia dei Tumori Neuroendocrini,
Perugia, IT;
Istituto Oncologico del Mediterraneo,
Viagrande (Catania), IT;
Università Federico II, Napoli, IT;
Istituto Europeo Oncologia, Milano, IT;
University of Genova, IT;
Università di Padova, IT;
Udine Hospital, IT;
University of Uppsala, SWE;
Athens School of Medicine, GREECE;
Erasmus University, Rotterdam, NL;
University Clinical Hospital,
Valladolid, ES

Local Comitee

L. Crinò
M. Tonato
F. Puma
M.E. Dottorini
V. Minotti
G. Angeletti
*on behalf of Multidisciplinary
Group for Diagnosis and
Treatment of Neuroendocrine
Tumors, Umbria Region Cancer
Network, Italy*

Scientific Secretariat

P. Ferolla (*coordinator*)
(Perugia, Italy)
A. Faggiano (Naples, Italy)
G. Vitale (Milan, Italy)
N. Daddi (Perugia, Italy)

Scientific Coordinator

E. Baudin (Paris, France)

Chairman

K. Oberg (Uppsala, Sweden)

Organizing Secretariat

ZETATOURS INTERNATIONAL
Via Amadeo, 3
20133 Milano
tel +39 02 7491361
fax +39 02 7385106
e-mail zt.meeting@libero.it



Workshop Location

VILLA DONINI

Via Deruta, 43
San Martino al Campo
06079 Perugia - Italy
Tel. and Fax 0039 75 609 132
www.postadonini.it
info@postadonini.it

II International Workshop (Expert Meeting)

CLINICAL MANAGEMENT OF THORACIC NEUROENDOCRINE TUMORS

Practical Clinical Recommendations



Experts Meeting
Perugia (Italy)
13-15 December 2010



AGENDA of the MEETING

13 December in the late afternoon: Arrival of the participants.

20.00-22.30 Dinner and instructions for the meeting

Day 1 : 14 December

- 08.30 **Introduction to the meeting**
- 09.00-11.00 **The choice of the preoperative diagnostic work-up**
- CT, Octreoscan, PET
 - Bronchoscopy
 - FNAB
 - Circulating Markers
 - paraneoplastic syndromes
 - MEN1 screening
 - evaluation of metastatic spread
 - creation of diagnostic algorithm (figure I)
- 11.00-13.00 **Follow-up**
- diagnostic techniques
 - timing
 - MEN1 patients
 - Ro and non RO
 - typical and atypical
 - high risk-low risk
 - evaluation of response to drug therapy
 - clinical trials
 - criteria of response to therapy
 - follow-up algorithm (figure II)
- 13.00-14.30 Lunch
- 14.30-17.00 **Medical Therapy I**
- There is a role for adjuvant therapy ? Which type ?
 - When to start medical therapy in non RO
 - Which is first line therapy?:
 - low burden tumors
 - high burden tumors
 - biological therapy
 - Chemotherapy
 - PPRT
 - Target therapy
 - locoregional therapies
- 17.00-17.30 Coffee break
- 17.30-19.00 **Medical Therapy II**
- Clinical trials
 - Criteria of tumor response
 - future prospectives
- 19.00 Conclusions of the day
- Dinner at Restaurant "Il Gradale"*

Day 2 : 15 December

- 8.30-10.30 **Brief revision and final discussion of the draft of clinical recommendations: (all)**
- Diagnostic work-up
 - Follow-up
 - Medical therapy
 - locoregional therapies
 - PPRT
 - clinical trials
 - Therapeutic algorithm (figure III)
- 10.30 **Presentation of a new clinical trial:**
- Multicenter 4-arm trial to evaluate the efficacy and safety of SOM230 and RAD001 alone or in combination or control in the treatment of patients with well differentiated neuroendocrine tumor of the LUNG**
- 12.30-13.00 Final considerations and End of the Meeting